Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Tredaniel

Showing results (11-20 of 22) with videos related to

Pageof 3
Sort By:
Respiratory Medicine|April 1, 1993
Diffuse panbronchiolitis: efficacy of low-dose erythromycinJ Tredaniel, G Zalcman, F Gerber, et al.
Bulletin Du Cancer|January 1, 1989
[Comparison of the antiemetic effectiveness of high-dose corticosteroids with synacthene in nausea induced by chemotherapy: results of a randomized study]P Brice, D Fiere, J L Gastaut, et al.
Leukemia & Lymphoma|April 7, 2000
A misleading pulmonary lesion in a patient with acute monoblastic leukemiaV Meignin, J Tredaniel, T Leblanc, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 20, 2009
The NER proteins are differentially expressed in ever smokers and in never smokers with lung adenocarcinomaD Planchard, J Domont, E Taranchon, et al.
Nouvelle Revue Francaise D'Hematologie|August 1, 1993
Residual mediastinal mass in malignant lymphoma: value of magnetic resonance imaging and gallium scanP Brice, J D Rain, J Frija, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 1, 1991
Cardiopulmonary toxicity after three courses of ABVD and mediastinal irradiation in favorable Hodgkin's diseaseP Brice, J Tredaniel, J J Monsuez, et al.
The European Respiratory Journal|February 1, 1992
The significance of a residual mediastinal mass following treatment for aggressive non-Hodgkin's lymphomasJ Tredaniel, P Brice, E Lepage, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 16, 2004
Phase II randomised trial comparing docetaxel given every 3 weeks with weekly schedule as second-line therapy in patients with advanced non-small-cell lung cancer (NSCLC)R Gervais, A Ducolone, J-L Breton, et al.
International Journal of Radiation Oncology, Biology, Physics|September 25, 1998
Predictive factors for late toxicity after endobronchial brachytherapy: a multivariate analysisC Hennequin, J Tredaniel, S Chevret, et al.
Lung Cancer (Amsterdam, Netherlands)|March 20, 2019
Nivolumab-refractory patients with advanced non-small-cell lung cancerA Costantini, V Fallet, J Corny, et al.
Pageof 3

Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
Respiratory Medicine|April 1, 1993
Diffuse panbronchiolitis: efficacy of low-dose erythromycinJ Tredaniel, G Zalcman, F Gerber, et al.
Bulletin Du Cancer|January 1, 1989
[Comparison of the antiemetic effectiveness of high-dose corticosteroids with synacthene in nausea induced by chemotherapy: results of a randomized study]P Brice, D Fiere, J L Gastaut, et al.
Leukemia & Lymphoma|April 7, 2000
A misleading pulmonary lesion in a patient with acute monoblastic leukemiaV Meignin, J Tredaniel, T Leblanc, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 20, 2009
The NER proteins are differentially expressed in ever smokers and in never smokers with lung adenocarcinomaD Planchard, J Domont, E Taranchon, et al.
Nouvelle Revue Francaise D'Hematologie|August 1, 1993
Residual mediastinal mass in malignant lymphoma: value of magnetic resonance imaging and gallium scanP Brice, J D Rain, J Frija, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 1, 1991
Cardiopulmonary toxicity after three courses of ABVD and mediastinal irradiation in favorable Hodgkin's diseaseP Brice, J Tredaniel, J J Monsuez, et al.
The European Respiratory Journal|February 1, 1992
The significance of a residual mediastinal mass following treatment for aggressive non-Hodgkin's lymphomasJ Tredaniel, P Brice, E Lepage, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 16, 2004
Phase II randomised trial comparing docetaxel given every 3 weeks with weekly schedule as second-line therapy in patients with advanced non-small-cell lung cancer (NSCLC)R Gervais, A Ducolone, J-L Breton, et al.
International Journal of Radiation Oncology, Biology, Physics|September 25, 1998
Predictive factors for late toxicity after endobronchial brachytherapy: a multivariate analysisC Hennequin, J Tredaniel, S Chevret, et al.
Lung Cancer (Amsterdam, Netherlands)|March 20, 2019
Nivolumab-refractory patients with advanced non-small-cell lung cancerA Costantini, V Fallet, J Corny, et al.
Pageof 3